|
Allele Symbol Allele Name Allele ID |
Ifngr1tm1Agt targeted mutation 1, Michel Aguet MGI:1857286 |
||||||||||||||||||||||||||||||||||||||||||||||||
| Summary |
11 genotypes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
| N |
• mice infected with the Urbani strain of severe acute respiratory syndrome coronavirus (SARS-CoV) or a recombinant isogenic mouse-adapted SARS-CoV (rMA15) that contains six virulence modifying mutations show no increase in susceptibility, pathogenesis, or histological outcomes to infection compared to wild-type controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• cuprizone-treated mice exhibit decreased initial demyelination, enhanced remyelination, decreased loss of mature oligodendrocyte, increased early appearance of oligodendroglial precursor cells, and delayed macrophage/microglia infiltration compared with similarly treated wild-type mice
• however, by the end of the toxic insult demyelination is normal
|
|
• initially, cuprizone-treated mice exhibit decreased demyelination compared with similarly treated wild-type mice
• remyelination following cuprizone treatment is enhanced compared to in similarly treated wild-type mice
• however, by the end of the toxic insult demyelination is normal
|
|
• following sciatic nerve injury, mice exhibit less mechanical allodynia compared with similarly treated wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• after induction of graft versus host disease
|
|
• reduction of Runx2 expression in bone marrow cells indicating impaired osteoblast differentiation
• reduction of alkaline phosphatase-expressing cells (osteoblasts) indicating impaired late differentiation of osteoblasts
|
|
• reduction of RANKL expression in bone marrow cells, indicating impaired osteoclast differentiation
|
|
• reduction of RANKL expression in bone marrow cells, indicating impaired osteoclast differentiation
|
|
• after induction of graft versus host disease, mice exhibit reduced numbers and proliferation of CD8+, CD4+, CD11b+, and CD19+ cells in the spleen compared with similarly treated wild-type cells
|
|
• after induction of graft versus host disease, mice exhibit reduced numbers of CD8+, CD4+, CD11b+, and CD19+ cells in the spleen compared with similarly treated wild-type cells
|
|
• after induction of graft versus host disease
|
|
• after induction of graft versus host disease
|
|
• after induction of graft versus host disease
|
|
• alphaGalCer-treated mice fail to exhibit an increase in circulating CXCL9 unlike similarly treated wild-type mice
|
|
• 6 hours following treatment with alphaGalCer compared to in similarly treated wild-type mice
|
|
• in the spleen and bone marrow after induction of graft versus host disease
|
|
• bacille Calmette-Guerin (BCG)-inoculated mice exhibit reduced depressive-like behavior in a forced swim and tail suspension tests and indoleamine 2,3-dioxygenase (IDO) activity compared with similarly treated wild-type mice
|
|
• after induction of graft versus host disease, mice exhibit early mortality, increased lung and skin pathology but decreased intestine pathology, increased IFN-gamma production in the spleen and bone marrow, increased spleen and bone marrow aplasia, decreased proliferation of hematopoietic stem/progenitor cells, and decreased lymphopoiesis compared with similarly treated wild-type mice
|
|
• reduction of Runx2 expression in bone marrow cells indicating impaired osteoblast differentiation
• reduction of alkaline phosphatase-expressing cells (osteoblasts) indicating impaired late differentiation of osteoblasts
|
|
• reduction of RANKL expression in bone marrow cells, indicating impaired osteoclast differentiation
|
|
• 45% reduction in bone volume
|
|
• mean number of osteocytes per cortical bone at the metaphyseal level is lower
|
|
• reduction of mineralized surfaces of bone of 4 week old mice
• reduction in mineral-apposition rate in 4 week old mice
• reduction of osteopontin expression within the trabeculae and in cortical bone indicating impaired mineralization
|
|
• reduction in bone-formation rate in 4 week old mice
|
|
• markers of bone resorption (RANKL and N-telopeptide) are reduced
|
|
• following treatment with alphaGalCer, mice fail to exhibit a reduction in the number of B16F10 tumors metastasizing to the lungs unlike similarly treated wild-type mice
• mice exhibit increased metastasis of B16F10 tumors to the lungs compared with wild-type mice
|
|
• lower circulating concentrations of the bone-formation marker osteocalcin
|
|
• alphaGalCer-treated mice fail to exhibit an increase in circulating CXCL9 unlike similarly treated wild-type mice
|
|
• 6 hours following treatment with alphaGalCer compared to in similarly treated wild-type mice
|
|
• reduction of RANKL expression in bone marrow cells, indicating impaired osteoclast differentiation
|
|
• after induction of graft versus host disease, mice exhibit reduced numbers and proliferation of CD8+, CD4+, CD11b+, and CD19+ cells in the spleen compared with similarly treated wild-type cells
|
|
• after induction of graft versus host disease
|
|
• after induction of graft versus host disease, mice exhibit reduced numbers of CD8+, CD4+, CD11b+, and CD19+ cells in the spleen compared with similarly treated wild-type cells
|
|
• after induction of graft versus host disease
|
|
• after induction of graft versus host disease
|
|
• after induction of graft versus host disease
|
|
• after induction of graft versus host disease, proliferation of hematopoietic stem/progenitor cells compared to in similarly treated wild-type mice
|
|
• bacille Calmette-Guerin (BCG)-inoculated mice exhibit reduced depressive-like behavior in a forced swim and tail suspension tests compared with similarly treated wild-type mice
|
Mouse Models of Human Disease |
DO ID | OMIM ID(s) | Ref(s) | |
| osteoporosis | DOID:11476 |
OMIM:166710 |
J:233116 | |
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Trpm2tm1.1Alp/Trpm2tm1.1Alp and Ifngr1tm1Agt/Ifngr1tm1Agt mice exhibit increased susceptibility to bacterial infection
|
• in mice infected with Listeria monocytogenes
(J:174397)
• in T. gondii-infected mice
(J:314959)
|
|
• MCMV-treated mice exhibit a 5-fold lower LD50 compared with similarly treated wild-type mice
|
|
• in MOG35-55-treated mice
|
 |
• the golgi apparatus is poorly developed, the rough ER is disorganized, and numerous mitochondria are seen in uNK cell at implantation sites at gestational day 12
|
|
|
• after day 10 of gestation increased numbers of uNK cells are found around the metrial gland compared to wild-type controls
|
|
• the ratio of IgG1 to IgG2a is increased in MOG35-55-treated mice compared to in similarly treated wild-type mice
(J:38363)
• levels of IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus
(J:101427)
|
|
• in MOG35-55-treated mice
|
|
|
• decrease in the number of apoptotic uNK cells in the metrial gland afte day 10 of gestation
• uNK cells at implantation sites fail to become heavily granulated and have poorly developed golgi apparati
|
|
• in T. gondii-infected mice
|
|
• in T. gondii-infected mice
|
|
• in mice infected with Listeria monocytogenes
|
|
• 10-fold in mice treated with LPS and D-GalN
|
|
• in the spleen cells of MOG35-55-treated mice
|
|
• in the spleen cells of MOG35-55-treated mice
|
|
• including increased mortality, spleen cell proliferation, spleen cell levels of IFN-gamma and TNF, and IgG1 to IgG2a ratio following treatment with MOG35-55
|
|
• mice tolerate up to 100 ug of LPS without demonstrating clinical symptoms unlike wild-type mice
• LPS-treated mice exhibit a faster recovery of total leukocyte counts compared with similarly treated wild-type mice
• mice treated with LPS and D-GalN exhibit resistance to endotoxic shock, including reduced serum TNF levels (10-fold) and hepatocellular necrosis, compared with similarly treated wild-type mice
|
|
• MCMV-infected mice develop chronic arteritis/aortitis, chronic productive infection, and reactivation of latency in spleen and lung explants unlike similarly treated wild-type mice
|
|
• mice infected with Listeria monocytogenes (Lm) exhibit decreased survival, increased bacterial burden in the spleen and liver, increased IL6 serum levels, and increased numbers of inflammatory abscesses in the liver with parenchyma destruction and necrosis in perivascular regions compared with similarly treated wild-type mice
(J:174397)
• T. gondii-infected mice exhibit increased parasite burden in the spleen, liver, and lung, and increased IFN-gamma and IL1b compared with wild-type mice
(J:314959)
|
|
• in mice infected with Listeria monocytogenes
(J:174397)
• in T. gondii-infected mice
(J:314959)
|
|
• T. gondii-exposed mice exhibit increased bacterial load, decreased activation of cerebral blood vessel endothelial cells, and reduced microglial activation compared with similarly treated wild-type mice
• however, recruitment and intracerebral cell movement is normal in T. gondii-exposed mice
|
|
• slightly more susceptible to MCMV viral infection than controls
|
|
• MCMV-treated mice exhibit a 5-fold lower LD50 compared with similarly treated wild-type mice
|
|
• increased susceptibility to Ectromelia virus
• 100% mortality by day 6-12 after primary infection infection
• elevated virus titers in all organs tested after primary infection but much improved after secondary infections
• survive secondary infections
|
|
|
• decrease in the number of apoptotic uNK cells in the metrial gland afte day 10 of gestation
• uNK cells at implantation sites fail to become heavily granulated and have poorly developed golgi apparati
|
|
|
• metrial glands are enlarged compared to wild-type controls
|
|
|
• after gestational day 10 the entire mesometrial decidua becomes progressively necrotic
• by gestational day 14 only a thin layer of tissue remains
|
|
|
• the golgi apparatus is poorly developed, the rough ER is disorganized, and numerous mitochondria are seen in uNK cell at implantation sites at gestational day 12
|
|
|
• after day 10 of gestation increased numbers of uNK cells are found around the metrial gland compared to wild-type controls
|
|
• in the spleen cells of MOG35-55-treated mice
|
|
• greater in mice infected with Listeria monocytogenes than in similarly treated wild-type mice
|
|
• mice fail to reject transplanted tumor cells originating from Ifngr1tm1Agt homozygotes or prevent blood vessel formation into the tumor mass unlike similarly treated wild-type mice
• however, T cell responses to the tumors are normal
|
|
• T. gondii-exposed mice exhibit decreased activation of cerebral blood vessel endothelial cells compared with similarly treated wild-type mice
• however, recruitment and intracerebral cell movement is normal in T. gondii-exposed mice
|
|
• mice fail to reject transplanted tumor cells originating from Ifngr1tm1Agt homozygotes or prevent blood vessel formation into the tumor mass unlike similarly treated wild-type mice
• however, T cell responses to the tumors are normal
|
|
• mice fail to prevent blood vessel formation into tumor masses from tumor cells originating from Ifngr1tm1Agt homozygotes unlike similarly treated wild-type mice
|
|
|
• after gestational day 10 the entire mesometrial decidua becomes progressively necrotic
• by gestational day 14 only a thin layer of tissue remains
|
|
|
• the golgi apparatus is poorly developed, the rough ER is disorganized, and numerous mitochondria are seen in uNK cell at implantation sites at gestational day 12
|
|
|
• after day 10 of gestation increased numbers of uNK cells are found around the metrial gland compared to wild-type controls
|
|
|
• the golgi apparatus is poorly developed, the rough ER is disorganized, and numerous mitochondria are seen in uNK cell at implantation sites at gestational day 12
|
|
|
• after day 10 of gestation increased numbers of uNK cells are found around the metrial gland compared to wild-type controls
|
|
• the ratio of IgG1 to IgG2a is increased in MOG35-55-treated mice compared to in similarly treated wild-type mice
(J:38363)
• levels of IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus
(J:101427)
|
|
• in MOG35-55-treated mice
|
|
|
• decrease in the number of apoptotic uNK cells in the metrial gland afte day 10 of gestation
• uNK cells at implantation sites fail to become heavily granulated and have poorly developed golgi apparati
|
|
• in T. gondii-infected mice
|
|
• in T. gondii-infected mice
|
|
• in mice infected with Listeria monocytogenes
|
|
• 10-fold in mice treated with LPS and D-GalN
|
|
• in the spleen cells of MOG35-55-treated mice
|
|
|
• the golgi apparatus is poorly developed, the rough ER is disorganized, and numerous mitochondria are seen in uNK cell at implantation sites at gestational day 12
|
|
|
• after day 10 of gestation increased numbers of uNK cells are found around the metrial gland compared to wild-type controls
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• in vesicular somatitis virus (VSV)-infected mice
|
|
• splenocytes proliferate against the antigen and a mitogen more vigorously than those from wild-type
|
|
• in trinitrophenyl-conjugated ovalbumin-treated mice
|
|
• in trinitrophenyl-conjugated ovalbumin-treated mice
|
|
• mice exhibit a slightly reduced CTL response against lymphocytic choriomeningitis virus (LCMV) infection with enhanced viral replication compared with similarly treated wild-type mice
|
|
• stimulation of splenocytes with an antigen or a mitogen induces a higher production of IFN-gamma than in wild-type
|
|
• stimulation of splenocytes with an antigen induces a higher production of IL-4, IL-6, IL-13 and IFN-gamma than in wild-type
• stimulation of splenocytes with a mitogen induces a higher production of IL-13
|
|
• following induction of experimental myasthenia gravis, mice exhibit less severe disease compared with wild-type mice
|
|
• exhibit increased incidence and severity of induced experimental autoimmune uveoretinitis compared to wild-type (59.3% vs. 40% of wild-type)
• upon uveoretinitis induction, see a significant infiltration of eosinophils into the eyes compared to wild-type
|
|
• following infection with Listeria monocytogenes, mice exhibit 100-fold increase in bacterial titers in the liver and 10-fold in the spleen compared to in similarly treated wild-type mice
|
|
• mice infected with vesicular somatitis virus (VSV) exhibit a 100- to 1000-fold increase in viral titers and increased lethality compared with similarly treated wild-type mice
• mice exhibit a slightly reduced CTL response against lymphocytic choriomeningitis virus (LCMV) infection with enhanced viral replication compared with similarly treated wild-type mice
|
|
• in vesicular somatitis virus (VSV)-infected mice
|
|
• tumor growth in tumor-bearing mice treated with Th-17-polarized cells from Tg(Tcra,Tcrb)9Rest cells is minimally delayed, and develop progressive disease
|
| N |
• mice show no liver injury on treatment with HBsAg-specific Th1 cells and HBsAg
|
|
• splenocytes proliferate against the antigen and a mitogen more vigorously than those from wild-type
|
|
• in trinitrophenyl-conjugated ovalbumin-treated mice
|
|
• in trinitrophenyl-conjugated ovalbumin-treated mice
|
|
• mice exhibit a slightly reduced CTL response against lymphocytic choriomeningitis virus (LCMV) infection with enhanced viral replication compared with similarly treated wild-type mice
|
|
• splenocytes proliferate against the antigen and a mitogen more vigorously than those from wild-type
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mice treated with collagen type 2 exhibit a 2- to 3-fold decrease early and 5- to 10-fold decrease at day 54 and 96, respectively, in anti-collagen type 2 IgG2a isotypes compared to in similarly treated wild-type mice
|
|
• with increased incidence, mean arthritic score, and maximal arthritic score and decreased anti-collagen type 2 IgG2a isotypes
• however, T cell response to induced arthritis is normal
|
|
• with increased incidence, mean arthritic score, and maximal arthritic score and decreased anti-collagen type 2 IgG2a isotypes
• however, T cell response to induced arthritis is normal
|
|
• mice treated with collagen type 2 exhibit a 2- to 3-fold decrease early and 5- to 10-fold decrease at day 54 and 96, respectively, in anti-collagen type 2 IgG2a isotypes compared to in similarly treated wild-type mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• compared to in Apoetm1Bres homozygotes
|
|
• compared to in Apoetm1Bres homozygotes
|
|
• whether fed standard chow or a Western type diet, mice exhibit an increase in apoA-I levels compared to in wild-type mice
|
|
• with smaller lesions, reduced lesion lipid content, and decreased lesion cellularity compared to in Apoetm1Bres homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• all mice are killed at as little as 10 PFU of MCMV
|
| N |
• mice infected with the Urbani strain of severe acute respiratory syndrome coronavirus (SARS-CoV) show no differences in susceptibility to infection from wild-type or single homozygous mice
|
|
• levels of IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus
|
|
• mice are 100,000-fold more susceptible to MCMV
|
|
• all mice are killed at as little as 10 PFU of MCMV
|
|
• increased susceptibility to Ectromelia virus
• 100% mortality by day 6-12 after primary infection infection
• elevated virus titers in all organs tested after primary infection but much improved after secondary infections
• survive secondary infections
|
|
• acutely sensitive to Sindbis
|
|
• levels of IgG2a and IgG2b neutralizing antibodies are reduced relative to controls after secondary infection with Ectromelia virus
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
Increased osteolytic lesion formation and enhanced osteoclast activity in Ifngr1tm1Agt/Ifngr1tm1Agt Tg(GZMB-Tax)#Lera/0 mice
|
• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice
|
|
• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice
• however, treatment with IFN-gamma inhibits tumor formation in vivo
|
|
• mice exhibit an increase in tartrate-resistant acid phosphatase-expressing osteoclasts compared to in Tg(GZMB-Tax)#Lera mice
|
|
• at 6 months, 89% of mice develop osteolytic skeletal tumors
• at 9 months, mice exhibit an increase in the number of osteolytic bone lesions compared with Tg(GZMB-Tax)#Lera mice
|
|
• mice exhibit decreased bone mineral density compared to in Tg(GZMB-Tax)#Lera mice
• however, IFN-gamma administration prevents
|
|
• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice
• however, treatment with IFN-gamma inhibits tumor formation in vivo
|
|
• at 6 months, 89% of mice develop osteolytic skeletal tumors
• at 9 months, mice exhibit an increase in the number of osteolytic bone lesions compared with Tg(GZMB-Tax)#Lera mice
|
|
• mice exhibit increased serum calcium levels compared with wild-type mice and Tg(GZMB-Tax)#Lera mice
• however, IFN-gamma administration prevents hypercalcemia
|
|
• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice
|
|
• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice
• however, treatment with IFN-gamma inhibits tumor formation in vivo
|
|
• mice exhibit an increase in tartrate-resistant acid phosphatase-expressing osteoclasts compared to in Tg(GZMB-Tax)#Lera mice
|
|
• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice
|
|
• mice develop more peripheral soft tissue tumors by 6 months compared with Tg(GZMB-Tax)#Lera mice
• however, treatment with IFN-gamma inhibits tumor formation in vivo
|
|
• mice exhibit an increase in tartrate-resistant acid phosphatase-expressing osteoclasts compared to in Tg(GZMB-Tax)#Lera mice
|
|
• osteoclast formation from bone marrow derived macrophage is enhanced compared to in Tg(GZMB-Tax)#Lera mice
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• some mice exhibit IgG deposits in the kidney unlike wild-type mice
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• mice exhibit reduced serum levels of kappa-chain rheumatoid factor and DNA auto-antibodies, lymphadenopathy, glomerulonephritis, renal immunoglobulin deposits, proteinuria, and end organ disease compared with Faslpr homozygotes
|
|
• mice exhibit reduced serum levels of kappa-chain rheumatoid factor and DNA auto-antibodies compared to in Ifnar1tm1Agt homozygotes
|
|
• DNA auto-antibodies (likely against single stranded DNA) are decreased compared with Faslpr homozygotes
|
|
• in some mice
|
|
• in some mice
|
|
• in some mice
|
|
• in some mice
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
• some mice exhibit IgG deposits in the kidney unlike wild-type mice
|
|
• compared with Faslpr homozygotes
|
|
• compared with Faslpr homozygotes
|
|
|
| ♀ | phenotype observed in females |
| ♂ | phenotype observed in males |
| N | normal phenotype |
|
• mild in some mice
|
|
• modestly compared with Ifngr1tm1Agt Faslpr or Ifnar1tm1Agt Faslpr double homozygotes
|
|
• some mice exhibit IgG deposits in the kidney unlike wild-type mice
|
|
• compared with Faslpr homozygotes
|
|
• mice exhibit reduced serum levels of kappa-chain rheumatoid factor and DNA auto-antibodies, lymphadenopathy, glomerulonephritis, renal immunoglobulin deposits, proteinuria, and end organ disease compared with Faslpr homozygotes
|
|
• compared with Ifngr1tm1Agt Faslpr double homozygotes
|
|
• mice exhibit reduced serum levels of kappa-chain rheumatoid factor and DNA auto-antibodies compared to in Ifngr1tm1Agt Faslpr or Ifnar1tm1Agt Faslpr double homozygotes
|
|
• compared with Ifngr1tm1Agt Faslpr or Ifnar1tm1Agt Faslpr double homozygotes at 24 weeks
|
|
• in some mice
|
|
• in some mice
|
|
• in some mice
|
|
• in some mice
|
|
• mild in some mice
|
|
• mild in some mice
|
|
• modestly compared with Ifngr1tm1Agt Faslpr or Ifnar1tm1Agt Faslpr double homozygotes
|
|
• some mice exhibit IgG deposits in the kidney unlike wild-type mice
|
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO) |
||
|
Citing These Resources Funding Information Warranty Disclaimer, Privacy Notice, Licensing, & Copyright Send questions and comments to User Support. |
last database update 04/23/2024 MGI 6.23 |
|
|
|
||
Analysis Tools